Ronald Evans

Ronald Evans

Direttore/Membro del Consiglio presso
The Salk Institute for Biological Studies
76 anni
Health Technology
Commercial Services
Consumer Services

Profilo

Ronald M.
Evans
is the founder of Ligand Pharmaceuticals, Inc. (1987), Syndax Pharmaceuticals, Inc. (2005), Synchronicity Pharma, Inc. (2008), Mitobridge, Inc. (2013), and Metacrine, Inc. (2014).
He is also the founder of Xenopharm, Inc., X-Ceptor Therapeutics, Inc., XTuit Pharmaceuticals, Inc. Dr. Evans's current jobs include Director & Professor at The Salk Institute for Biological Studies, Director at American Association for Cancer Research, Member at National Academy of Sciences, Member at American Academy of Arts & Sciences, and Member at National Academy of Medicine (United States).
Dr. Evans received his doctorate degree from the University of California, Los Angeles in 1974 and his undergraduate degree from the same university in 1970.

Posizioni attive di Ronald Evans

SocietàPosizioneInizio
Direttore/Membro del Consiglio -
Corporate Officer/Principal 25/01/2010
Corporate Officer/Principal 25/01/2010
Corporate Officer/Principal 25/01/2010
Direttore/Membro del Consiglio -

Precedenti posizioni note di Ronald Evans

SocietàPosizioneFine
METACRINE, INC. Fondatore 23/03/2023
Fondatore -
Fondatore -
Fondatore -
░░░░░░░░░░ ░░░░ ░░░░░░░░░ -
Vedi nel dettaglio l'esperienza di Ronald Evans

Formazione di Ronald Evans

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

88

Relazioni di 1° grado

14

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private14

Health Technology

Consumer Services

Health Technology

Commercial Services

Consumer Services

Commercial Services

Commercial Services

Commercial Services

Commercial Services

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Mercati
  2. Insiders
  3. Ronald Evans
- 40%: I migliori strumenti riservati agli abbonati per individuare le opportunità di investimento di domani.
g
:
:
ENTRA ORA